Insulet Co. (NASDAQ:PODD) EVP Eric Benjamin Sells 12,394 Shares

Insulet Co. (NASDAQ:PODD) EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Insulet Price Performance

Shares of PODD opened at $280.35 on Friday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $282.86. The firm has a market capitalization of $19.66 billion, a PE ratio of 48.01, a PEG ratio of 3.50 and a beta of 1.22. The company’s 50-day moving average is $267.25 and its 200-day moving average is $235.25. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. During the same period last year, the firm earned $0.71 earnings per share. Equities analysts forecast that Insulet Co. will post 3.22 EPS for the current year.

Hedge Funds Weigh In On Insulet

A number of hedge funds have recently bought and sold shares of PODD. Marshall Wace LLP bought a new position in Insulet during the second quarter worth about $99,978,000. Baillie Gifford & Co. increased its holdings in Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after buying an additional 389,639 shares during the period. Mizuho Securities USA LLC increased its holdings in Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after buying an additional 320,416 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after buying an additional 193,839 shares during the period. Finally, Westfield Capital Management Co. LP increased its holdings in Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after buying an additional 163,388 shares during the period.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Citigroup increased their target price on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. TD Cowen increased their price target on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Sanford C. Bernstein assumed coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Morgan Stanley increased their price target on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, JPMorgan Chase & Co. increased their price target on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average price target of $272.81.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.